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Abstract To clarify the neuroprotective property of
ceruloplasmin and the pathogenesis of aceruloplasmin-
emia, we generated ceruloplasmin-deﬁcient (CP
-/-) mice
on the C57BL/10 genetic background and further treated
them with a mitochondrial complex I inhibitor, rotenone.
There was no iron accumulation in the brains of CP
-/-
mice at least up to 60 weeks of age. Without rotenone
treatment, CP
-/- mice showed slight motor dysfunction
compared with CP
?/? mice, but there were no detectable
differences in the levels of oxidative stress markers
between these two groups. A low dose of rotenone did not
affect the mitochondrial complex I activity in our mice,
however, it caused a signiﬁcant change in motor behavior,
neuropathology, or the levels of oxidative stress markers in
CP
-/- mice, but not in CP
?/? mice. Our data support that
ceruloplasmin protects against rotenone-induced oxidative
stress and neurotoxicity, probably through its antioxidant
properties independently of its function of iron metabolism.
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Introduction
Ceruloplasmin (Cp) is proposed to have multiple biological
functions, including oxidation of ferrous iron (Fe
2?) and
oraganic amines, copper transport, radical scavenging, and
prooxidant activities [1–3]. In particular, the signiﬁcance of
Cp in iron transport through its ferroxidase activity has
been well established, In the brain, Cp is mainly produced
by astrocytes, especially perivascular astrocytes, and is
localized on the membrane of astrocytes as a GPI-anchored
form [4]. GPI-anchored Cp oxidizes Fe
2? released from
perivascular astrocytes into ferric iron (Fe
3?), and allows it
to bind to transferrin [5–7]. Transferrin-bound iron is the
main source of iron for neurons, thus, Cp facilitates iron
uptake of neurons by its ferroxidase activity.
In the Cp-deﬁcient state (aceruloplasminemia), Fe
2? in
the interstitial space cannot be oxidized for uptake by
transferrin. This might result in an increase of non-trans-
ferrin-bound iron (NTBI), and excessive NTBI then enters
in astrocytes or other brain cells [5]. Finally, excessive
cytosolic Fe
2? promotes the generation of cytotoxic
hydroxyl radicals (OH
•), leading to the oxidative damage
to neuronal cells. Indeed, a huge amount of iron accumu-
lation is observed in various brain regions of aceruloplas-
minemia patients [8–10]. There are several lines of
evidence supporting that increased oxidative stress is clo-
sely associated with neuronal cell death in this disease [9–
13]. Therefore, aceruloplasminemia is a good model dis-
ease to investigate the pathogenetic link between iron
accumulation and neurodegeneration. To assess this issue,
we generated Cp-deﬁcient (CP
-/-) mice by a targeted
disruption of the ceruloplasmin gene (CP) on the BALB/c
genetic background [14]. Contrary to our expectation,
however, our CP
-/- mice showed no iron accumulation in
the brain or apparent neurological dysfunction, whereas
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liver [14]. The conversion of genetic background of CP
-/-
mice from BALB/c to C57BL/10 also failed to develop
iron accumulation (unpublished data).
It is widely believed that iron accumulation is involved
in the pathogenesis of several neurodegenerative diseases
such as Parkinson’s disease and Alzheimer’s disease [7,
15–17]. In Parkinson’s disease, iron accumulation pro-
motes a-synuclein aggregation in the dopaminergic neu-
rons of the substantia nigra [15–17]. Furthermore,
excessive iron reduces the mitochondrial complex I activity
in dopaminergic neurons [18]. Therefore, rotenone, a
selective mitochondrial complex I inhibitor, has been used
to reproduce the neuropathological ﬁndings of Parkinson’s
disease [19–26]. The neurotoxic properties of rotenone are
mediated via OH
• generation following the inhibition of
complex I activity in the substantia nigra [20]. To date,
many researchers have attempted to attenuate the neuro-
toxic effects of rotenone using various therapeutic agents in
in vitro and in vivo models [27–29]. On the other hand,
there are several clinical observations suggesting that a
decreased oxidative activity of Cp is closely involved in the
pathogenesis of Parkinson’s disease [30, 31].
Our CP
-/- mice with both BALB/c and C57BL/10
genetic background showed no detectable iron accumula-
tion. Therefore, this study aimed to investigate the neuro-
protective properties of Cp independently of iron
metabolism. For this aim, we treated the mice with rote-
none to enhance oxidative stress and neurotoxicity.
Experimental Procedure
Experimental Animals
The derivation of the CP
-/- mice with the C57BL/10
genetic background used in this study has been already
described [14, 32]. All animals were housed in a con-
trolled-temperature environment maintained under a 12 h/
12 h light/dark cycle and provided with free access to food
and water. All animal procedures were in accordance with
the National Institutes of Health Guide for the Care and
Use of Laboratory Animals and they were approved by the
Institutional Animal Care and Use Committee of Shinshu
University.
Genotyping
Tail tips were placed in a cell lysis solution (QIAGEN)
supplemented with proteinase K (20 mg/ml), shaken
overnight at 55 C, and then centrifuged for 5 min at
15,0009g at 4 C to remove insoluble material. The
supernatant was directly subjected to PCR ampliﬁcation
with the Ampdirect Plus Kit (Shimadzu, Japan) for geno-
typing. The PCR conditions and primer sequences were
described previously [14]. The genotype of the mice was
reconﬁrmed by immunoblotting for serum Cp [14].
Rotenone Treatment
We used 13-week-old CP
?/? and CP
-/- mice in this study.
The mice were treated with 10 mg/kg/day rotenone or
vehicle for 28 days using an osmotic pump (Alzet; DU-
RECT Corporation, USA) subcutaneously, as previously
described [32]. To see the effects of Cp under rotenone-
induced neurotoxic conditions, we established the follow-
ing four types of mice: (1) rotenone-untreated, wild-type
mice (CP
?/?/R-); (2) rotenone-untreated, Cp-deﬁcient
mice (CP
-/-/R-); (3) rotenone-treated, wild-type mice
(CP
?/?/R ?); and (4) rotenone-treated, Cp-deﬁcient mice
(CP
-/-/R ?).
Behavioral Analysis
In all animal groups, body weight and motor function were
determined weekly during the period of treatment with
rotenone or vehicle. Behavioral analysis was done by
footprint assessment and accelerated rotarod test [33, 34].
Footprint assessment was performed to detect deﬁcits in
motor coordination and gait abnormalities. To obtain
footprints, the hind- and forepaws of mice were coated with
black and red nontoxic paint, respectively. The animals
were then allowed to walk along a plastic-lined, 65 cm-
long and 4 cm-wide walkway into an enclosed box with
12 cm-high walls on either side. The footprint patterns
were analyzed for stride length (the average distance of
forward movement between each stride) and step alterna-
tion (the average distance from the left or right front
footprint/hind footprint overlap) [33].
Motor coordination, balance, and learning were tested
with an accelerating rotarod (3.3 cm in diameter). The
mice were allowed to run while the speed of the rotarod
was gradually increased from 4 to 40 rpm. The mice were
tested three times in each trial, and the mean latency to fall
off the rotarod was recorded [34].
Brain tissue Preparation
After 4 weeks of treatment with rotenone or vehicle, all
mice were deeply anesthetized with diethyl ether inhala-
tion. The mice were euthanized and their whole brains
were removed. One hemisphere of the removed brain was
weighed and homogenized in a 10-fold volume of a high
salt buffer (10 mM TrisHCl, pH 7.5, 0.5 M NaCl, 10%
sucrose) supplemented with a cocktail of protease
inhibitors (Complete Mini, Roche). The samples were
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were stored at -80 C until analysis. The other hemisphere
of the brain was ﬁxed overnight in 10% formalin for
immunohistochemical analysis.
Measurement of Mitochondrial Complex I Enzyme Activity
We measured the mitochondrial complex I activities in
brain and liver tissue homogenates using the Complex I
Enzyme Activity Microplate Assay Kit (MitoSciences,
USA). The samples recovered from whole tissue homog-
enates (protein concentration; 3.0 mg/ml for brain and
5.5 mg/ml for liver) were used for the assay according to
the manufacturer’s instructions. The activity was expressed
as the change in absorbance at 450 nm per minute (mOD/
min).
Assessment of Oxidative Stress Markers
Western Blotting
Brain tissues were homogenized and boiled for 5 min in a
buffer containing 10% SDS, 70 mM Tris–HCl (pH 6.7),
10 mM EDTA, and 5% b-mercaptoethanol. Equal
amounts of brain proteins were then separated on a grad-
uated 12% SDS–polyacrylamide gel and electrotransferred
onto a polyvinylidene diﬂuoride membrane. The blot was
incubated at 4 C overnight with the following primary
antibodies: anti-Cp polyclonal antibody (Cp, 1:500,
DAKO), anti-4-hydroxynonenal monoclonal antibody
(HNE, 1:500, JaICA, Japan), and anti-Hexanoyl-Lys-
adduct monoclonal antibody (HEL, 1:500, JaICA, Japan).
After three washes, the membrane was incubated with
secondary antibody (horseradish peroxidase-conjugated
anti-mouse or rabbit IgG, 1:5,000, BioRad) and developed
using ECL Western blotting detection reagents (Thermo,
USA). To ensure that equal amounts of proteins were
loaded, the same membranes were reprobed with anti-
glyceraldehyde 3-phosphate dehydrogenase monoclonal
antibody (GAPDH, 1:5,000, Millipore).
Immuno-Assay
To measure the levels of the lipid peroxidation product
4-hydroxynonenal (HNE) in brain tissue, we used the
4-HNE-histidine ELISA Kit (OxiSelect HNE-His Adduct
ELISA Kit, Cell Biolabs, New Zealand) according to the
manufacturer’s instructions. As the anti-HNE-His antibody
was a monoclonal mouse IgG, we used magnetic beads
linked to protein G (Dynabeads Protein G, Invitrogen
Dynal, USA) to remove endogenous IgG from brain tissues
[35]. To capture the endogenous IgG with Dynabeads
protein G, the same amount (5 lg) of brain proteins was
added to 50 ll of beads and incubated with rotation over-
night. Then the tube was placed onto a magnet to separate
the beads from solution, and the supernatant was used for
analysis.
The carbonyl contents of brain tissues were assayed with
the Protein Carbonyl Enzyme Immuno-assay Kit (Biocell
PC Test, BioCell Crop, New Zealand) according to the
manufacturer’s instructions. Absorbance was measured at
450 nm and expressed as nmol carbonyl/mg protein.
Immunohistochemistry
The parafﬁn-embedded brain tissues were cut at 10 lm.
The sections were deparafﬁnized and hydrated through
graded alcohol. These sections were ﬁrst microwaved in
0.1 M sodium citrate, pH 6.5. They were then incubated in
3% aqueous hydrogen peroxide (H2O2) to remove endog-
enous peroxidase activity, and in phosphate buffered saline
containing 10% goat serum for 30 min. Subsequently, the
sections were incubated overnight at 4 C with primary
antibodies: HNE (1:100) and HEL (1:50). The sections
were then incubated with anti-mouse or rabbit IgG sec-
ondary antibody (1:300, DAKO), streptavidin-HRP conju-
gate (1:300, GIBCO BRL), and reacted with
diaminobenzidine (0.3 mg/ml, SIGMA) in 50 mM Tris
buffer (pH 7.4) with 0.001% H2O2. Finally, the sections
were counterstained with hematoxylin.
Statistical Analysis
All values are presented as mean ± standard error (SEM).
Statistical analysis of data was performed using two-way
analysis of variance (ANOVA) or repeated-measures
ANOVA, followed by post hoc Student’s t-test to deter-
mine the signiﬁcance of differences between two groups.
The analysis was performed using software Excel Toukei
2010 (Social Survey Research Information, Tokyo, Japan).
Statistical signiﬁcance was attributed as P\0.05.
Results
Effects of Rotenone Treatment on Motor Function
All mice completed the protocol without any troubles in
general health. There were no signiﬁcant differences in
body weight between the four experimental groups (data
not shown). By western blotting, rotenone treatment did
not change the level of Cp expression in CP
?/? mice
(Fig. 1a). There were no signiﬁcant differences in mito-
chondrial complex I enzyme activity of brain (Fig. 1b) and
liver tissue homogenates (Fig. 1c) among the four experi-
mental groups.
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123In the footprint test, CP
-/-/R? mice tended to develop
gait abnormalities, such as a shorter stride length and an
irregular placement of the fore- and hind-limbs (Fig. 2a).
Stride length signiﬁcantly decreased in CP
-/-/R- mice
(0 w: 64.0 ± 4.0 mm vs. 4w :5 4 . 4± 3.3 mm, P\0.05,
n = 8) and CP
-/-/R? mice (0 w: 63.5 ± 1.3 mm vs. 4w :
53.6 ± 2.3 mm, P\0.05, n = 6) during the experiment,
while there was no obvious change in CP
?/? mice, even
with rotenone treatment. There was no difference in stride
length between CP
-/-/R- and CP
-/-/R? mice. Step
alternation of CP
-/- mice appeared more irregular than in
CP
?/? mice before treatment, but this was not statistically
signiﬁcant. Step alteration gradually worsened with rote-
none treatment in CP
-/- mice. In CP
?/? groups, step
alteration tended to get worse with rotenone treatment, but
the difference was not signiﬁcant between CP
?/?/R- and
CP
?/?/R? mice after 4 weeks. At the end of rotenone
treatment, step alteration was more conspicuous in CP
-/-/
R? mice than CP
?/?/R- or CP
?/?/R? mice (Fig. 2c).
The time spent on the rotarod was not different before
rotenone treatment between the four mouse groups, and
increased over time in all groups. The fall latency of CP
?/
?/R- mice drastically increased at 4 weeks (0 w:
10.8 ± 2.7 s vs. 4 w: 41.2 ± 4.0 s, P\0.05, n = 5).
However, after 4 weeks, CP
-/-/R- mice and CP
-/-/R?
mice showed shorter fall latencies than CP
?/?/R- mice
(Fig. 2d). There was no signiﬁcant difference in the fall
latency between the CP
-/-/R- and CP
-/-/R? mice.
Detection of Oxidative Stress Markers
Western blotting showed that the signals indicative of HNE
and HEL were enhanced in the brains of CP
-/-/R? mice
compared with mice from the other three groups (Fig. 3a,
b). Consistent with the western blotting data, ELISA
analyses showed a signiﬁcant increase in HNE and protein
carbonyls in CP
-/-/R? mice (Fig. 3c, d). Rotenone treat-
ment did not change the levels of HNE or carbonyl proteins
in CP
?/? mice.
Neuropathological and Immunohistochemical Findings
Histopathological ﬁndings were grossly normal in the four
experimental groups. Iron staining detected no iron accu-
mulation in the brains of CP
-/- mice before and after
rotenone treatment (data not shown). The immunoreactiv-
ity for HNE and HEL in the cytoplasms of the striatal
neurons was more conspicuous in CP
-/-/R? mice than
CP
?/?/R- or CP
-/-/R- mice (Fig. 4). Even without
rotenone treatment, the immunoreactivity was apparent in
CP
-/-/R- mice, but not in CP
?/?/R- mice (Fig. 4).
Discussion
We have generated CP
-/- mice in both the BALB/c and
C57BL/10 genetic background to investigate the patho-
genesis of aceruloplasminemia, but neither of the mice
showed iron accumulation in the brain at least up to 40 or
60 weeks of age [14, 32]. In this study, therefore, we used a
selective mitochondrial complex I inhibitor, rotenone, to
enhance oxidative stress and to see whether Cp has a
protective effect against oxidative neuronal damage.
Rotenone decreases the viability of TH-immunoreactive
Fig. 1 Western blotting of brain homogenates using an anti-Cp
antibody (a) and measurement of mitochondrial complex I activity in
the brain (b) and liver (c). Cp expression was unchanged between
CP
?/?/R- and CP
?/?/R? mice (a). There was no signiﬁcant
difference in mitochondrial complex I enzyme activity of brain
(b) and liver tissue homogenates (c) among the four experimental
groups (n = 5)
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123Fig. 2 Analysis of motor
function. a Representative
footprints after the 4-week
administration of 10 mg/kg
rotenone or vehicle. The
forepaws and hindpaws were
colored with red and black ink,
respectively. The dotted lines
indicate stride length. The
irregular distance between the
fore- and hindpaws in a CP
-/-/
R? mouse is indicated by the
bidirectional arrow. The
quantiﬁcation of the stride
length (b) and step alternation
(c) of footprint patterns in CP
?/
?/R-, CP
-/-/R-, CP
?/?/R?,
and CP
-/-/R? mice are shown
(n = 7–10). d Fall latency in
the rotarod test (4–40 rpm)
(n = 4–5). *P\0.05 in
comparison with control
(CP
?/?/R-)
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123dopaminergic neurons in vivo and in vitro, and is fre-
quently used to investigate the pathogenesis of Parkinson’s
disease [19–26]. According to the reported dosage of
rotenone in mice (2.5–100.0 mg/kg/day for 4–9 weeks)
[21, 23–26], we used rotenone at a comparatively low-
dosage (10 mg/kg, 4 weeks). Thus, all the mice completed
the protocol without any problems in their general health
and the mean body weight was not signiﬁcantly different
between the four groups examined.
Rotenone did not cause a signiﬁcant change in motor
behavior, neuropathology, or the levels of oxidative stress
markers in the presence of Cp in this study. On the other
hand, it brought about an obvious motor dysfunction and
increased levels of oxidative stress markers in the absence
of Cp. At the end of the 4-week rotenone treatment, CP
-/-/
R? mice showed a slow and irregular gait with small steps,
and they fell from the rotarod more easily than CP
?/?/R-
mice. The levels of oxidative stress markers were increased
in CP
-/-/R? mice when compared with CP
?/?/R- or
CP
-/-/R- mice. In addition, we previously reported that
immunoreactivity for acrolein and ubiquitin was enhanced
in the brains of CP
-/-/R? mice [32]. Mitochondria are
easily exposed to oxidative damage because they utilize
large amounts of oxygen and iron, and contain numerous
redox enzymes [36, 37]. In fact, there is a marked reduction
in the activity of the respiratory chain complexes I and IV
in the brains of aceruloplasminemia patients [11]. Thus,
from the viewpoint of enhanced oxidative stress in the
brain, our CP
-/- mice treated with a low dose of rotenone
will be a more faithful model for aceruloplasminemia than
conventional CP
-/- mice.
But, rotenone treatment in our mice did not affect the
mitochondrial complex I activities, probably because of the
low dosage. Under this condition, however, CP
-/- mice,
not CP
?/? mice, showed a signiﬁcant increase of oxidative
stress markers in the brain and motor dysfunction. Rote-
none is believed to cause neuron death by an inhibition of
the mitochondrial complex I activities, but Choi et al. have
suggested that neuronal cell death induced by rotenone is
independent of mitochondrial complex I inhibition [38].
The present study may support that rotenone-induced
neurotoxicity is mediated through alternative pathways
other than mitochondrial complex I inhibition, and that
such pathways are enhanced by Cp deﬁciency.
Our CP
-/- mice with or without rotenone treatment
showed no iron accumulation in the brain as far as we
observed up to 60 weeks of age. The question is
how Cp prevents neuronal cells from rotenone-induced
Fig. 3 Western blotting (a,
b) and immune-assay (c, d) for
oxidative stress markers.
Western blotting for HNE (a),
and HEL (b) is shown. The
arrows indicate endogenous
IgG (a, b). Immuno-assay for
HNE (c) and protein carbonyls
(d) is shown
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123neurotoxicity under the circumstances without iron accu-
mulation. Cp is considered to oxidize non-iron substrates
such as catecholamines and aromatic amines [1, 2, 39]. For
example, Cp oxidizes the neurotoxin, 6-hydroxydopamine,
which is an intermediate in the formation of dopamine and
melanins. 6-hydroxydopamine undergoes spontaneous
autooxidation to yield several reactive oxygen species
including H2O2 and OH
•. Unlike spontaneous autooxida-
tion, 6-hydroxydopamine oxidation by Cp does not result
in the production of H2O2 and OH
• [2, 39]. Thus, one
possible interpretation is that enhanced oxidative stress in
our CP
-/-/R? mice could be due to a loss of Cp-mediated
oxidation of non-iron substrates. Moreover, Atanasiu et al.
have shown that Cp is capable to scavenge peroxyl,
superoxide radicals, and OH
• even after heat inactivation
of its oxidase activity [40]. These data strongly indicate
that Cp, besides its preventive antioxidant properties, has
chain-breaking antioxidant property [40]. This is another
possibility to explain that CP
-/-/R? mice showed motor
dysfunction and increased oxidative stress markers when
compared with CP
?/?/R- mice. The antioxidant properties
of Cp other than its ferroxidase activity may also explain
Fig. 4 Immunohistochemistry
for oxidative stress markers.
Immunohistochemical staining
using anti-HNE (a–d) and anti-
HEL (e–h) antibodies in the
striatum is shown. CP
?/?/R-
(a, e), CP
-/-/R- (b, f), CP
?/?/
R? (c, g), and CP
-/-/R? mice
(d, h). Scale bars = 20 lm
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123why our CP
-/-/R- mice showed motor dysfunction when
compared with CP
?/?/R- mice. Even, if it is the case, we
speculate that an increase of oxidative stress markers in our
CP
-/-/R- mice was too subtle, or locally restricted to be
detected by our assay methods using whole brain
homogenates.
In summary, our CP
-/- mouse model treated with
rotenone indicates that Cp plays an important role in the
neuroprotection against oxidative stress, even without
apparent misregulation of iron homeostasis. To further
elucidate the pathogenesis of aceruplasminemia, it will be
needed to clarify how the alternative functions of Cp, other
than ferroxidase activity, is involved in this disease.
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